Thomas received his graduate degree from Linköping Institute of Technology. He has headed a number of Swedish companies before he founded Recipharm AB, a Swedish listed pharmaceutical contract development and manufacturing company, in 1995. With Thomas as the CEO, the organization has grown to be a major player with approx. 9000 employees, at 30 facilities located in 10 countries, offering pharmaceutical companies full service by taking products all the way from early development to commercial production. In addition, Thomas is Managing partner at Flerie Invest and at the Board of several companies including Kahr Medical Ltd, Provell Pharmaceuticals LLC, and Sixera Pharma AB.
Bernhard Kirschbaum PhD
Bernhard studied and spent his early career as a researcher in biochemistry and physiological chemistry at the University of Konstanz, Germany. He received his PhD in 1989 and moved on to work at the Rockefeller University in New York and the Pasteur Institute in Paris. Subsequently, he joined the pharmaceutical industry where he covered a broad range of technological and disease areas including Vice President Discovery Research, Global Head of Therapeutic Domains “Thrombosis & Angiogenesis” for Sanofi-Aventis and various senior positions at Aventis and Hoechst Marion Roussel respectively. He joined Merck KGaA in 2005 to become head of Global Research and Early Development at Merck Serono and member of the Pharmaceutical Executive Committee, before joining various biotech companies as chairman and board member.
Maarten de Château MD & PhD
Maarten is a bio-entrepreneur working primarily in oncology and rare diseases. He did basic research at Lund University, Harvard Medical School and Uppsala University. He worked as a sell-side analyst at two investment banks: Aragon and Swedbank Markets. For the last 15+ years he has been involved in clinical development at Sanofi and Sobi, before co-founding Cormorant Pharmaceuticals. Cormorant brought a mAb against IL-8 into the clinic as an immune-oncology agent and was sold to BMS in 2016. In the same year he co-founded Buzzard Pharmaceuticals, where a potent IL-1 inhibitor is being developed as an immune oncology agent. He also serves as CEO of Sixera Pharma, developing a NCE treatment for the rare skin disease Nethertons, and is VP Medical Strategy and Innovation at Camurus. He currently also serves on the boards of Atrogi, OxThera, Cavis Technologies and Beactica.
Ted Fjällman PhD
Ted is Venture Partner in Flerie Invest, a Swedish investment firm with biotech investments in Sweden, the UK, the Netherlands and Israel. He joined the board after an investment in Amarna in 2019. He is also the CEO of Prokarium, a London-based biotech developing microbial immunotherapies and vaccines. Ted has held a clinical research position at Sahlgrenska University Hospital and has worked as a strategy consultant at Sweden’s Royal Academy of Engineering Sciences, where he coordinated the country’s national innovation strategy. He is an active member of the UK BioIndustry Association (BIA) and has served on the Management Board of the international Bacterial Vaccines Network (BactiVac). He also co-founded and continues to serve on the board of Tekiu, an international knowledge transfer broker active within healthcare, environmental tech and smart cities.
Pim Berger MSc
Pim is the CEO and co-founder of the Dutch IT company Schuberg Philis and has been one of Amarna’s pioneering informal investors for over 10 years. He was managing director in the Netherlands of SiteSmith Inc., a US-based Internet infrastructure management services company. In 2000 SiteSmith Inc. was acquired by Metromedia Fiber Network Inc. (MFN) in a transaction valued at approximately $1.4 billio, following which Pim became Senior Vice President of MFN’s European Region. In a management buyout by Pim and two partners in 2003 the Benelux subsidiary of MFN Inc. became Schuberg Philis. Before this, Pim held several senior executive positions at the Dutch IT companies Pink Elephant and PinkRoccade (now part of KPN). Pim holds a master’s degree in computer engineering and economics from the Hogeschool IJsselland.
Guillaume Jetten PhD
Guillaume is the CFO of the Netherlands based MercachemSyncom, a leading European mid-sized contract research organization. Guillaume is a seasoned senior biotech executive, that has been working in the healthcare industry for most of his career. He held positions at Merck, Sharpe & Dohme, as well as served as Chief Financial Officer (CFO) of Wolters Kluwer Health. He also worked as CFO for Galapagos between 2009 and 2014. Guillaume holds a master’s degree in economics from the University of Maastricht and is a Certified Registered Accountant.
Markwin Velders PhD
Markwin is an independent entrepreneur with 25 years of experience, in the fields of research, development, operations and management. He was awarded a PhD in Molecular Immunology from Leiden University in the Netherlands. After transferring from the US academical to the Dutch biopharmaceutical sector, Markwin served, among several other management positions, four years as CSO at the Dutch biotech company AM-Pharma, with responsibility for R&D. In 2013 he joined the Dutch biotech T-Cell Factory (TCF) where he played a key role in the acquisition of the company to form Kite Pharma EU B.V. Markwin following joined Kite in 2015 where he managed the R&D of new CAR T receptors alongside the implementation of Kite’s new manufacturing facility for cell therapy in the Netherlands. In addition, Markwin is chairman of the board of HollandBio, the branch association for Biotech in the Netherlands and supervisory board member at ISA Pharmaceuticals in Leiden.